Jaguar Health Begins Phase 2 Trial for Crofelemer in Pediatric MVID Patients

Jaguar Health, Inc. announced the randomization of the first patient in a Phase 2 clinical trial of crofelemer for pediatric patients with Microvillus Inclusion Disease (MVID). This trial aims to assess the safety and efficacy of crofelemer, an oral treatment, for this ultrarare intestinal condition. Initial results from a related trial in Abu Dhabi showed crofelemer reduced the need for parenteral support by up to 27% in an MVID patient. This is significant as such support, crucial yet risky, is the standard care for MVID.

Crofelemer has shown potential in modifying disease progression and enhancing life quality by reducing severe diarrhea-related symptoms. Jaguar anticipates further results from ongoing studies by 2025. This could potentially lead to accelerated regulatory approval in the EU and possibly the US, given the disease's rarity. The trial's progress marks a step forward in developing new treatments for MVID.